Key result
Intranasal and intramuscular administration of AAV vectors expressing SARS-CoV-2 spike proteins elicited robust and sustained neutralizing antibodies in mice for over a year.
Why the study?
The COVID-19 pandemic continues to pose significant health challenges despite existing vaccines, warranting evaluation of recombinant AAV expressing SARS-CoV-2 spike proteins.
Population
Mice
Comparison
Intramuscular vs intranasal administration of AAV5-spike, AAV5-spike stabilized trimer, and AAV44.9-spike
Design
Animal study
Follow-up
Over a year
Authors
Loading...
Sustained anti-spike responses via AAV vectors in mice; hypothesis-generating for durable vaccine platforms, human trials needed before clinical consideration.
Ji et al. (2025) studied SARS-CoV-2 vaccination. AAV expressing SARS-CoV-2 spike proteins vs. Untransduced control mice / AAV5-GFP was evaluated on Anti-spike IgG levels and neutralizing activity. Intranasal and intramuscular administration of AAV vectors expressing SARS-CoV-2 spike proteins elicited robust and sustained neutralizing antibodies in mice for over a year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: